Idanna Innocenti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications

Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.

Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.

Journal: Hematological oncology
Published: December 17, 2025

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances
Published: October 22, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology
Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances
Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances
Published: October 15, 2025

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Journal: Blood advances
Published: June 13, 2025

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Journal: Blood advances
Published: March 18, 2025

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.

Journal: Leukemia
Published: January 09, 2025

Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Journal: Blood advances
Published: January 07, 2025

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation.

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation.

Journal: Hematological oncology
Published: December 09, 2024

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.

Journal: Hematological oncology
Published: December 02, 2024

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Journal: Hematological oncology
Published: November 15, 2024
Showing 1-12 of 109

Last Updated: 09/26/2026